Letters Glucagon-like peptide-1 drugs

Use of GLP-1 analogues needs great caution

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d1478 (Published 08 March 2011) Cite this as: BMJ 2011;342:d1478
  1. John S Yudkin, emeritus professor of medicine1,
  2. Richard Lehman, senior research fellow2,
  3. Harlan M Krumholz, Harold H Hines Jr professor of medicine3
  1. 1University College London, London, UK
  2. 2Department of Primary Care, University of Oxford, Oxford OX3 7LF, UK
  3. 3Yale University, New Haven, CT, USA
  1. j.yudkin{at}ucl.ac.uk

Glucagon-like peptide-1 analogues (GLP-1) for type 2 diabetes are being increasingly recommended for use as third line treatment for obese patients with type 2 diabetes. However, such recommendations ignore Wilding and Hardy’s caution: “Data on long term effects of GLP-1 analogues on vascular complications are not yet available from current trials.”1 In other words, we currently have no idea whether their use is beneficial or harmful in relation …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe